N-1,2,3-Triazole-Isatin derivatives in lymphoma cell lines

Abstract

Molecular hybrid constructs are an interesting approach to merge individual pharmacophores with different mechanisms of action, potentially decreasing side effects. The 1,2,3-triazole unit is present in many bioactive compounds and it is characterized by its ability to be stable towards hydrolysis to increase the compounds lipophilicity. Hybrids containing this pharmacophore together with isatin and its analogues have shown a wide spectrum of potential therapeutic activities, also against cancer. Burke et al. have recently reported new N-1,2,3-triazole-isatin hybrids with in vitro anti- tumor activity in solid tumor cell lines (RSC Medicinal Chemistry 2022; EP3400938). Here, we present the in vitro anti-lymphoma activity and structure activity relationships (SAR) of 9 N-1,2,3-triazole-isatin hybrids.